^(125)I粒子植入联合肝动脉栓塞化疗及肝复乐片治疗原发性肝癌的临床观察  

The Clinical Observation of ^(125)I Particles Implantation Combined TACE and Ganfule Tablet Treat Primary Liver Cancer

作　　者：张文华 梁春辉 贾文玲 唐海涛 梁莹 

机构地区：[1]甘肃省武威市肿瘤医院,甘肃武威733000

出　　处：《中国医药指南》2015年第25期12-13,共2页Guide of China Medicine

摘　　要：目的研究125I粒子植入联合肝动脉栓塞化疗(TACE)及口服肝复乐片对原发性肝癌的治疗效果。方法回顾性分析116例确诊的原发性肝癌患者,A组37例(125I粒子植入联合TACE及肝复乐治疗组),B组36例(TACE联合肝复乐治疗组),C组43例(单纯TACE治疗组),3组均于治疗后第3、6、12个月行CT扫描进行疗效评价,分别比较3组治疗后6、12个月的生存状态。3组有效率及生存状态比较均采用卡方检验,以P<0.05为差异有统计学意义。结果治疗3、6、12个月后,A组的有效率分别为78.4%、83.8%、24.3%,显著高于B组的44.4%、38.89%、8.3%和C组的39.5%、18.6%、4.6%,差异有统计学意义(P<0.05);治疗6、12个月后,A组生存率分别为89.2%和32.4%,明显高于B组的69.4%、16.7%和C组的46.5%、9.3%,差异有统计学意义(P<0.05)。治疗6个月后,B组的有效率和生存率分别为38.89%、69.4%,明显高于C组的18.6%、46.5%,差异有统计学意义(P<0.05)。结论 I125粒子植入联合TACE及肝复乐片是治疗肝癌的有效方法,具有良好的应用前景。Objective To investigate the treatment effect of 125 I particles implantation combined TACE and Ganfule treat primary liver cancer. Methods Retrospective analysis of 116 cases of patients which was diagnosed with primary liver cancer, A group had 37 cases（125I particles implantation combined TACE and Ganfule treatment group）, B group had 36 cases（TACE and Ganfule treatment group）, C group had 36 cases（only TACE treatment group）, three groups were CT scan and curative effect evaluation after 3, 6, 12 months treatment, three groups were compared living condition after treatment for 6 months and 12 months. The efficient and living condition of three groups of comparison adopt chi-square test, P〈0.05 was statistically significant. Results After 3, 6, 12 months treatment, the efficient of group A respectively was 78.4%, 83.8% and 24.3%, significantly higher than group B which was 44.4%, 38.89%, 8.3%, and higher than group C which was 39.5%, 18.6% and 4.6%, the difference was statistically significant（P〈0.05）. After 6 and 12 months treatment, the survival rates of group A respectively was 89.2% and 32.4% significantly higher than group B which was 69.4%, 16.7%, and higher than group C which was 46.5%, 9.3%. The difference was statistically significant（P〈0.05）. After 6 months treatment, the efficient rates and survival rates of group B respectively were 38.89% and 16.7% significantly higher than group C which was 18.6%, 46.5%, the difference was statistically significant（P〈0.05）. Conclusion 125 I particles implantation combined TACE and Ganfule tablet is an effective method for treatment of liver cancer, has a good application prospect.

关 键 词：125I粒子组织间植入 肝动脉栓塞化疗 肝复乐片 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]